Article Text
PDF
Statistics from Altmetric.com
OpenUrlCrossRefPubMed
Q Is olanzapine more effective for treating neurocognitive deficits than risperidone or haloperidol in people with schizophrenia?
METHODS
Design:
Randomised controlled trial.
Allocation:
Concealed.
Blinding:
Double blind.
Follow up period:
52 weeks.
Setting:
39 sites, USA and Canada; July 1999 to September 2000.
Patients:
414 people with schizophrenia or schizoaffective disorder (DSM-IV; mean age 39 years; 71% men). Exclusions: <18 or >55 years old; fewer than two positive items on the Positive and Negative Symptoms scale with a score ⩾4; score <18 on the Brief Psychiatric Rating Scale; non-English speaking; <2 years since first diagnosis, treatment or hospitalisation; neurological disorder; head injury; serious illness; untreated hypothyroidism or hyperthyroidism; agranulocytosis; pregnant or nursing; substance dependence; treatment with depot antipsychotics, reversible monoamine oxidase inhibitor, clozapine, …
Footnotes
For correspondence: Richard S E Keefe, Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC 27710, USA; richard.keefe{at}duke.edu
Source of funding: Lily Research Laboratories, USA.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.